Madopar (Benserazide Hydrochloride, Levodopa)

Madopar, an antiparkinson combination of levodopa and benserazide, is indicated for several dopaminergic‑responsive movement disorders where restoring central dopamine improves motor function.

• Parkinson's disease: reduces bradykinesia, rigidity, tremor and motor fluctuations, leading to improved daily activities and quality of life.
• Parkinsonian syndrome: alleviates motor deficits such as stiffness and slowed movements that arise from secondary Parkinsonism, drug‑induced parkinsonism, or vascular causes.
• Levodopa‑responsive dystonia: provides symptomatic relief of sustained muscle contractions by enhancing central dopamine levels, thereby reducing abnormal posturing.

• Madopar combines levodopa, a precursor that crosses the blood‑brain barrier and is decarboxylated to dopamine, with benserazide, a peripheral aromatic L‑amino‑acid decarboxylase inhibitor. Benserazide prevents conversion of levodopa outside the central nervous system, thereby increasing the amount of levodopa that reaches the brain. Once in the brain, levodopa is transformed into dopamine, replenishing depleted dopaminergic pathways that control motor movement.

Madopar may cause a range of adverse reactions, which are grouped by frequency and clinical significance.

Common Side Effects

• Nausea: feeling of stomach upset, often occurring at treatment initiation.
• Dizziness: light‑headed sensation that may worsen when standing quickly.
• Orthostatic hypotension: drop in blood pressure upon standing, causing faintness.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Dyskinesia: involuntary, erratic movements that can be disabling.
• Hallucinations: visual or auditory disturbances, especially in older patients.
• Severe hypotension or cardiac arrhythmias: potentially life‑threatening blood pressure drops or irregular heart rhythms.

When prescribing Madopar, clinicians should observe several precautionary measures to ensure safe use.

• Dose titration: start with a low dose and increase gradually to minimize side effects.
• Monitor for dyskinesia: watch for involuntary movements that may develop with chronic therapy.
• Assess renal and hepatic function: adjust therapy in patients with impaired organ function.
• Avoid abrupt discontinuation: sudden stop can precipitate worsening Parkinsonism or neuroleptic malignant‑like syndrome.
• Use with food: taking the tablet with meals can reduce gastrointestinal irritation.
• Store at room temperature: keep in the original container, protect from moisture and light.

Madopar interacts with several medicines; understanding the level of interaction helps guide safe co‑administration.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): can cause hypertensive crisis when combined with levodopa.
• Antipsychotics that block dopamine receptors (e.g., haloperidol): reduce therapeutic effect and may worsen Parkinsonism.
• High‑dose pyridoxine (vitamin B6): accelerates peripheral conversion of levodopa, diminishing central availability.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: additive blood‑pressure lowering may increase risk of orthostatic hypotension.
• Selective serotonin reuptake inhibitors (SSRIs): may enhance serotonergic activity, requiring monitoring for serotonin syndrome.
• Other dopaminergic drugs (e.g., dopamine agonists): may increase risk of dyskinesia and require dose adjustments.